Biosidus Brings New Bioreactor Plant Online to Expand Agalsidase Beta Supply for Fabry Disease
核心洞察
Biosidus (搜索), an Argentine biotechnology company, announced its new bioreactor plant is now operational, increasing biologics production capacity to support potential international demand.
The expansion reinforces manufacturing reliability and continuity of treatment for agalsidase beta, the company's biosimilar enzyme replacement therapy for Fabry disease (搜索).
Biosidus (搜索) launched agalsidase beta in Argentina in 2025 and is now advancing international expansion, prepared to evaluate extraordinary supply requirements where regulatory pathways allow.
Biosidus (搜索), an Argentine biotechnology company with more than four decades of experience in the development and manufacturing of biosimilar medicines, announced that its new bioreactor plant is now operational, increasing the company's biologics production capacity and reinforcing its ability to support potential international demand.
The expansion strengthens Biosidus (搜索)' industrial platform at a time when healthcare systems are placing increasing emphasis on manufacturing reliability, continuity of treatment and diversified sources of complex biologic medicines.
Agalsidase Beta: A Biosimilar Milestone for Rare Disease
Developed and manufactured in Argentina, Biosidus (搜索)' agalsidase beta — its biosimilar enzyme replacement therapy for Fabry disease (搜索) — represents a significant milestone in the company's biotechnology platform and its growing focus on treatments for rare diseases.
With additional production capacity, Biosidus (搜索) is strengthening its international supply capabilities and is prepared to engage with partners and health authorities evaluating sustainable and reliable sources of agalsidase beta supply.
"Continuity of treatment is particularly critical for patients living with rare and chronic diseases. Expanding our productive capacity reinforces our commitment to making Biosidus (搜索)' biotechnology capabilities available to healthcare systems seeking sustainable and reliable access to high-quality biologic medicines," said Mario Koch, Director of Rare Diseases.
International Expansion and Supply Strategy
After launching agalsidase beta in Argentina in 2025, Biosidus (搜索) is advancing the international expansion of its program and is available to evaluate extraordinary supply requirements in markets where the applicable regulatory pathways allow it.
The new bioreactor capacity is part of Biosidus (搜索)' broader strategy of combining scientific capabilities, local manufacturing, industrial investment and international expansion to increase access to complex biologic therapies.
About Biosidus
Biosidus (搜索) is an Argentine biotechnology company specializing in the development, manufacturing and commercialization of biosimilar medicines. With more than 40 years of experience in biotechnology and a presence in international markets, the company develops and manufactures complex biologic medicines across multiple therapeutic areas.